Leading UK Pharmacies trust Deltera
Deltera provides the digital framework to deliver Foundayo, Eli Lilly's breakthrough oral GLP-1, safely and at scale. As the first swallow-whole weight loss tablet with no food or water restrictions, Foundayo removes a major barrier to patient uptake — and our digital PGD ensures every consultation meets strict clinical criteria and regulatory standards across your entire estate. Guide patients through eligibility, titration, and safety screening with the same GP-standard governance you trust for Mounjaro and Wegovy.
A Fully Digital Clinical Platform
Integrated Bookings and Payments
Secure & Connected Patient Records
Ditch the paperwork with secure digital records. Deltera automatically shares treatment summaries with the patient’s and sends the required notification to their GP instantly.
Training and Eligibility Requirements
To ensure clinical safety and regulatory compliance, all practitioners using this PGD must meet the following professional standards:
- Professional Registration: Must be a registered healthcare professional (e.g., Pharmacist) with a valid GPhC or PSNI registration and personal professional indemnity insurance.
- Clinical Competency: Practitioners must be self-certified as competent in the specific clinical area covered by this PGD and stay up to date with relevant national guidelines (e.g., The Green Book or NICE clinical summaries).
- Mandatory Training: Current certification in Basic Life Support (BLS) and the management of anaphylaxis is required for all injectable services.
- PGD Authorisation: The practitioner must have read and signed the PGD document within the Deltera Clinical Dashboard, with the authorisation counter-signed by the designated organisational lead or Superintendent.
- Premises Standards: Services must be conducted in a private consultation room that meets national standards for patient confidentiality and clinical safety.
Speak to the clinicians behind the platform
We understand the complexities of PGDs and clinical governance in the UK. Schedule a meeting with our team to see how we can help you navigate the changing landscape of community pharmacy.
Access related PGDs
FAQs
What is Foundayo (orforglipron)?
Foundayo is an oral, once-daily GLP-1 receptor agonist developed by Eli Lilly for chronic weight management. Unlike injectable GLP-1s or other oral options, it's a small-molecule tablet that can be taken at any time of day with or without food or water — making it one of the most convenient weight loss treatments available through community pharmacy.
Can pharmacies offer Foundayo under a PGD?
Yes. Deltera's Foundayo PGD allows trained pharmacists to assess, prescribe, and supply Foundayo to eligible patients without requiring a traditional GP prescription. The digital workflow guides your team through BMI verification, medical history, and red-flag screening, so every consultation is compliant and audit-ready from the outset.
How does Foundayo differ from Mounjaro and Wegovy injections?
Foundayo is a tablet rather than an injection, with no titration-day food restrictions and no needles — a strong option for needle-averse patients or those wanting a simpler routine. Dosing starts at 0.8mg and titrates upward in stages, similar in principle to injectable GLP-1s, but delivered as a once-daily pill that's swallowed whole.
Who is eligible for the Foundayo PGD?
Foundayo is approved for adults with obesity, or adults who are overweight with a weight-related medical condition, alongside a reduced-calorie diet and increased physical activity. As with all Deltera weight management PGDs, the platform's built-in safety logic flags contraindications — including thyroid cancer history and MEN 2 — before treatment can proceed.
Still have questions?
Our team are here to support you.
Discover the Deltera Platform
The Deltera Platform digitalises your private pharmacy services, providing the complete pharmacy software package to offer a full range of Patient Group Directions (PGDs). Gain the oversight and efficiency you need to thrive.
